PHAT
vs
S&P 500
PHAT
S&P 500
Over the past 12 months, PHAT has significantly outperformed S&P 500, delivering a return of +129% compared to the S&P 500's +14% growth.
Stocks Performance
PHAT vs S&P 500
Performance Gap
PHAT vs S&P 500
Performance By Year
PHAT vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Phathom Pharmaceuticals Inc
Glance View
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company is headquartered in Florham Park, New Jersey and currently employs 77 full-time employees. The company went IPO on 2019-10-25. The Company’s pipeline product candidate, vonoprazan is an oral small molecule potassium-competitive acid blocker (P-CAB). P-CABs are a class of medicines that block acid secretion in the stomach. Vonoprazan has an anti-secretory effect and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease (GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.
